Multi-Parameter Phenotypic Analysis of Members of Chronic Lymphocytic Leukemia Clones Identifies Distinct Proliferative and Resting/Re-Entry Compartments with Discrete Gene Expression Profiles.

Abstract 668 Background. In vivo studies of deuterium ( 2 H) incorporation into newly-synthesized DNA of chronic lymphocytic leukemia (B-CLL) B cells indicate that the disease is dynamic, with ongoing birth and death of individual members of a leukemic clone. Therefore, a detailed phenotypic analysis might define the “life cycle” of subpopulations of leukemic cells within a B-CLL clone, thereby identifying recently-born members and members born earlier. Such an extended phenotype could enable structural and genetic characterization of the intra-clonal heterogeneity that birth and death create, and thereby help understand the biology of B-CLL cells and define novel cell surface markers or marker combinations as therapeutic targets. Methods. Our previous studies indicated that B-CLL clones could be subdivided into three populations based on relative densities of expression of CXCR4 and CD5. The CXCR4 dim CD5 bright subpopulation is enriched in cells with 2 H-labeled, newly-synthesized DNA and contains significantly more Ki-67 + and MCM6 + cells than CXCR4 int CD5 int cells within the same clone. These latter cells in turn are enriched for the same parameters compared to the CXCR4 bright CD5 dim fraction. We have now identified other markers associated with the CXCR4 dim CD5 bright subpopulation (“proliferative compartment”) and the CXCR4 bright CD5 dim (“resting/re-entry compartment”) in B-CLL. PBMC from 20 B-CLL cases were subjected to multi-parameter immunofluorescent, flow cytometric analyses to define the expression of CD11a, CD20, CD23, CD27, CD38, CD47, CD49d, CD52, or Fcƒ×RII on the CD19 + CXCR4 dim CD5 bright and CD19 + CXCR4 bright CD5 dim B-CLL cell subpopulations. Companion studies were performed on Ki-67 + and Ki-67 - subpopulations. Finally, gene expression profiling was performed on CXCR4 dim CD5 bright , CXCR4 int CD5 int , and CXCR4 bright CD5 dim subsets of 12 B-CLL cases using the Illumina HumanWG-6 platform. Results. Compared to CXCR4 bright CD5 dim cells within a clone, the CXCR4 dim CD5 bright compartment contained significantly more cells expressing CD23, CD52 (both p dim CD5 bright proliferative compartment, 11 related to proliferation (e.g., NAPSA, MARCKS, CCND2), 10 were involved in cell signaling and activation (e.g., GPR183, ADAP1), and 4 related to cell movement and migration (e.g., CXCR3). In the CXCR4 bright CD5 dim resting/re-entry compartment, 12 of the 25 most overexpressed genes were involved in apoptosis and cell death (e.g., RXR2, HRK), 7 in cell signaling (e.g., ADARB1, RAB37) and 5 in cell movement and migration (e.g., MDK, IRS2). Conclusions. These studies defined a reciprocal, extended surface membrane phenotype that distinguishes cells of the proliferative and the resting/re-entry compartments in B-CLL. This phenotype is based both on the percent of expressing cells and on the density of expression of well-defined surface molecules. In addition, gene expression analyses identified genes differentially expressed between the two compartments. These data support the notion that cells in these two compartments are a phenotypic continuum, with the former having divided recently and trafficking from the location where division occurred and the latter having divided earlier, being less robust, and attempting to traffic back to a lymphoid microenvironment to obtain survival signals. We suggest that targeting these two populations with appropriate monoclonal antibodies, many of which are currently in clinical trials in B-CLL and other B-cell lymphoproliferative disorders, may have a beneficial effect. Although this approach may not immediately diminish the bulk of the leukemic mass, it would preferentially eliminate the small fraction of cells that sustains a B-CLL clone and the fraction of cells that maintain a B-CLL clone after receiving survival signals, thereby permitting the remaining cells to die spontaneously. Disclosures: Allen: Antisoma: Research Funding.